利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

45 条记录 (耗时 0.031 秒)

    Human anti-human interleukin-18 antibody, fragment thereof and method for using same
    34.
    发明授权
    Human anti-human interleukin-18 antibody, fragment thereof and method for using same 失效
    人抗人白介素-18抗体及其片段及其使用方法

    公开(公告)号：US07491803B2

    公开(公告)日：2009-02-17

    申请号：US10555074

    申请日：2004-04-30

    申请人： Kazuhisa Sugimura ,  Kenji Nakanishi ,  Toshihiro Nakashima

    发明人： Kazuhisa Sugimura ,  Kenji Nakanishi ,  Toshihiro Nakashima

    IPC分类号： C07K16/00 ,  C12N15/09

    CPC分类号： C07K16/244 ,  C07K2317/21 ,  C07K2317/565

    摘要： A human-derived human anti-human IL-18 antibody of the present invention is an antibody against human IL-18, the antibody including: an H-chain complementarity determining region consisting of (a) a polypeptide consisting of amino-acid sequences represented by SEQ ID NOS: 4 to 6, or (b) a polypeptide which is a mutant of the polypeptide (a) and which serves as the H-chain complementarity determining region; and an L-chain complementarity determining region against human interleukin-18 consisting of (c) a polypeptide consisting of amino-acid sequences represented by SEQ ID NOS: 10 to 12, or (d) a polypeptide which is a mutant of the polypeptide (c) and which serves as the L-chain complementarity determining region. This makes it possible to provide a human anti-human IL-18 antibody and a method for using the antibody.

    摘要翻译： 本发明的人衍生的人抗人IL-18抗体是针对人IL-18的抗体，所述抗体包括：H链互补决定区，其由（a）由氨基酸序列表示的多肽组成 通过SEQ ID NO：4至6，或（b）多肽（a）的突变体并用作H链互补决定区的多肽; 和由（c）由SEQ ID NO：10至12表示的氨基酸序列组成的多肽的人白介素-18组成的L链互补决定区，或（d）多肽突变体的多肽（ c）并且其用作L链互补决定区。 这使得可以提供人抗人IL-18抗体和使用该抗体的方法。

    Method For Improving Antibody
    35.
    发明申请
    Method For Improving Antibody 有权
    改善抗体的方法

    公开(公告)号：US20080138860A1

    公开(公告)日：2008-06-12

    申请号：US11815838

    申请日：2006-02-07

    申请人： Masaharu Torikai ,  Toshihiro Nakashima

    发明人： Masaharu Torikai ,  Toshihiro Nakashima

    IPC分类号： C12P21/00 ,  C07K16/00

    CPC分类号： C07K16/00 ,  C07K16/1271 ,  C07K16/2818 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/567 ,  C07K2317/94

    摘要： The present invention provides for a method for improving properties of an antibody such as an expression level and stability. A method for obtaining an antibody with an improved expression level and/or stability by modifying a human antibody or a humanized antibody, characterized by that at least any one of the amino acid residues at position 8, 12, 15 or 18 (according to Kabat numbering) in a light chain variable region (hereinafter referred to as “VL chain”) of a human antibody or a humanized antibody is substituted with a different amino acid other than proline or cysteine, and a human antibody or a humanized antibody or a human antibody fragment or a humanized antibody fragment with an improved expression level and/or stability which are obtained by said method.

    摘要翻译： 本发明提供了改善抗体性质的方法，例如表达水平和稳定性。 通过修饰人抗体或人源化抗体获得具有改善的表达水平和/或稳定性的抗体的方法，其特征在于，第8,12,15或18位的氨基酸残基中的至少任一种（根据Kabat 编号）在人抗体或人源化抗体的轻链可变区（以下称为“VL链”）中被除脯氨酸或半胱氨酸以外的不同氨基酸，人抗体或人源化抗体或人 抗体片段或具有通过所述方法获得的改善的表达水平和/或稳定性的人源化抗体片段。

    Human-type anti-blood coagulation factor VIII antibody
    36.
    发明授权
    Human-type anti-blood coagulation factor VIII antibody 失效
    人类抗凝血因子VIII抗体

    公开(公告)号：US07214785B2

    公开(公告)日：2007-05-08

    申请号：US10344514

    申请日：2002-06-11

    申请人： Toshihiro Nakashima ,  Masato Yuguchi

    发明人： Toshihiro Nakashima ,  Masato Yuguchi

    IPC分类号： C07H21/04

    CPC分类号： C07K7/06 ,  A61K38/00 ,  C07K7/08 ,  C07K14/755 ,  C07K16/36 ,  C07K2317/21 ,  C07K2317/622 ,  G01N33/86

    摘要： The present invention provides a human antibody against blood coagulation factor VIII (hereinafter also referred to as “FVIII”) and an antibody fragment that binds to human FVIII and specifically inhibits the coagulation activity of human FVIII. ScFv display phage libraries, prepared by using scFv DNAs constructed by random combinations of immunoglobulin VH chain genes and VL chain genes from lymphocytes from hemophilia A patients, is reacted with FVIII immobilized to a solid phase via anti-FVIII monoclonal antibody, and scFv clones capable of binding to FVIII are cloned to reveal VH and VL chains of FVIII-specific antibody.

    摘要翻译： 本发明提供了针对凝血因子VIII（以下也称为“FVIII”）的人抗体和与人FVIII结合并特异性抑制人FVIII凝血活性的抗体片段。 通过使用通过免疫球蛋白VH链基因的随机组合构建的scFv DNA和来自血友病A患者的淋巴细胞的VL链基因制备的ScFv显示噬菌体文库通过抗FVIII单克隆抗体与能够固定在固相上的FVIII反应，以及具有能力的scFv克隆 克隆与FVIII结合以揭示FVIII特异性抗体的VH和VL链。

    Human anti-amyloid β peptide antibody and fragment of said antibody
    40.
    发明授权
    Human anti-amyloid β peptide antibody and fragment of said antibody 失效
    人抗淀粉样蛋白 肽抗体和所述抗体的片段

    公开(公告)号：US07763249B2

    公开(公告)日：2010-07-27

    申请号：US11579072

    申请日：2005-04-21

    申请人： Kazuhisa Sugimura ,  Toshihiro Nakashima

    发明人： Kazuhisa Sugimura ,  Toshihiro Nakashima

    IPC分类号： A61K39/395 ,  C07K16/18 ,  C12P21/08

    CPC分类号： G01N33/6896 ,  A61K31/7088 ,  A61K48/00 ,  C07K16/18 ,  C07K2317/21 ,  C07K2317/622 ,  G01N2333/4709 ,  G01N2800/2821

    摘要： A human anti-amyloid β peptide (hereinafter referred to as “Aβ”) antibody that binds to Aβ to thereby inhibit aggregation of Aβ molecules, and a fragment of said antibody are provided. The antibody and a fragment thereof according to the present invention, comprising a variable region of a human-derived anti-Aβ antibody, strongly reacts with Aβ to thereby inhibit its aggregation and hence may be used as a medicament for the prophylaxis and treatment of Alzheimer dementia.

    摘要翻译： 人类抗淀粉样蛋白 与A＆bgr结合的肽（以下称为“A＆bgr”）抗体; 从而抑制A＆bgr的聚集; 分子和所述抗体的片段。 根据本发明的抗体及其片段，其包含人衍生的抗A＆Bgr的可变区; 抗体与A＆bgr强烈反应; 从而抑制其聚集，因此可以用作预防和治疗阿尔茨海默氏痴呆的药物。